Search for: "Nemours Corp. v. United States" Results 21 - 40 of 57
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
26 May 2015, 7:42 am
  As of the time of trial, the state of the art did not include a genetic marker for SJS/TEN. [read post]
25 Apr 2015, 11:03 am by Schachtman
Third, the Manual authors state that the doubling argument assumes the “[n]onacceleration of disease. [read post]
23 Jan 2015, 9:30 am
Bayer Corp., 727 F.3d 300 (3d Cir. 2013), and Marcus v. [read post]
17 Oct 2013, 5:00 am by Bexis
  Comment k could correspond to Led Zeppelin, and state of the art might be The Who.And it seems that, for each of these bands, there’s a song we really like that gets slighted (in our opinion) when it comes to air time on classic rock stations. [read post]
5 Jul 2013, 5:00 am by Bexis
Surgidev Corp., 899 P.2d 576, 591 (N.M. 1995) (“evidence of compliance with FDA regulations was properly submitted to the jury for consideration”); United Blood Services v. [read post]
29 Nov 2012, 1:23 pm by Bexis
[T]he United States [FDA] requires the tablet manufacturers . . . to account for and warn of a drug’s properties. [read post]
16 Jul 2012, 5:25 am by Sean Wajert
Fluor Corp., 220 S.W.3d 712, 717-18 (Mo. 2007); Donovan v. [read post]
2 Dec 2011, 6:29 am by Schachtman
DuPont Nemours & Co., W.D.N.Y., No. 07-CV-0267S(Sr) Weist v. [read post]
26 Feb 2011, 3:47 pm
Cir. 1996) ("The nonobviousness of the accused device, evidenced by the grant of a United States patent, is relevant to the issue of whether the change therein is substantial. [read post]
16 Jan 2011, 7:36 am by Vincent LoTempio
The United States Patent and Trademark Office (USPTO) granted an all-time high 219,614 United States utility patents in 2010 – up 31 percent over 2009. [read post]